OTHER
Therapeutics
Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants
| The first 150 words of the full text of this article appear below. |
In women at risk of preterm delivery, does magnesium sulphate provide neuroprotection for the fetus?
Included studies compared magnesium sulphate (administered intravenously, intramuscularly, or orally) with placebo, no treatment, or an alternate treatment (control) as a neuroprotective agent for the fetus when given to women at risk of preterm delivery. Studies in which the primary aim was other than fetal neuroprotection (eg, treatment of pre-eclampsia or preterm labour) were included if long-term infant neurological outcomes were reported. Outcomes were fetal/infant death, cerebral palsy, neurological impairment, and maternal side effects (such as nausea, vomiting, headache, palpitations, and flushing).
Cochrane Pregnancy and Childbirth Groups Trials Register (which contains results of searches of Cochrane Central Register of Controlled Trials, Medline, 30 journals, and major conference proceedings) was searched in August 2008 for randomised controlled trials (RCTs). 5 articles describing 6 RCTs (n = 6145 babies) met the selection criteria; in 4 RCTs,
Institute for Women's Health, University College London, London, UK
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
